Delivery Order SPE2DB22D2005-SPE2DB25FJRL2
- Not listed
- The Defense Logistics Agency awarded a $3,163.85 delivery order to AmerisourceBergen Drug Corp for 100 capsules of Vyvanse 50 mg, a prescription stimulant medication commonly used to treat attention-deficit/hyperactivity disorder. The contract, awarded on July 24, 2025, with completion targeted for July 25, 2025, carries a firm fixed price structure with no set-aside designation, indicating it was competitively awarded. Performance will be fulfilled from AmerisourceBergen's location in...
- The Defense Logistics Agency awarded a delivery order valued at $6,677.69 to AmerisourceBergen Drug Corp for 100 capsules of Vyvanse 20 mg, a prescription stimulant medication commonly used to treat attention deficit hyperactivity disorder. The contract was competitively awarded without set-aside provisions and carries a firm fixed price structure with an ultimate completion date of July 31, 2025. AmerisourceBergen will perform this delivery from its corporate headquarters in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $3,047.13 to AmerisourceBergen Drug Corp for 100 capsules of Vyvanse 20 mg, a prescription stimulant medication commonly used to treat attention deficit hyperactivity disorder. The award, issued on July 30, 2025, with an ultimate completion date of July 31, 2025, was competitively awarded with no set-aside designation. AmerisourceBergen, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will fulfill...
- The Defense Logistics Agency awarded a $3,007.07 delivery order to AmerisourceBergen Drug Corp for 100 capsules of Vyvanse 50 mg, a prescription stimulant medication commonly used to treat attention deficit hyperactivity disorder. The contract was awarded on July 18, 2025, with an ultimate completion date of July 21, 2025, under firm fixed pricing with no set-aside designation. Performance will occur at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency awarded a $2,090.85 delivery order to AmerisourceBergen Drug Corp for 100 capsules of Vyvanse 30 mg, a prescription stimulant medication commonly used to treat attention deficit hyperactivity disorder (ADHD). This competitively awarded, firm fixed-price delivery order was issued on August 7, 2025, with an ultimate completion date of August 8, 2025, and represents a direct fulfillment of pharmaceutical supply needs through the federal medical procurement system. The...
- The Defense Logistics Agency awarded a delivery order valued at $1,398.46 to AmerisourceBergen Drug Corp for 100 capsules of Vyvanse 60 mg, a prescription stimulant medication commonly used to treat attention deficit hyperactivity disorder and binge eating disorder. The contract, issued on July 18, 2025, with an ultimate completion date of July 21, 2025, utilizes firm fixed pricing and represents a non-competitive set-aside award. The place of performance is AmerisourceBergen's corporate...
- The Defense Logistics Agency awarded a delivery order valued at $7,637.24 to AmerisourceBergen Drug Corp for 100 capsules of Vyvanse 10 mg, a prescription stimulant medication commonly used to treat attention deficit hyperactivity disorder. This firm fixed-price delivery order, awarded on August 8, 2025, with an ultimate completion date of August 11, 2025, was issued without a set-aside designation and represents a competitively awarded transaction. The pharmaceutical supplies will be...
- The Defense Logistics Agency awarded a $22,628.60 delivery order to AmerisourceBergen Drug Corp for 100 capsules of Vyvanse 10 mg, a prescription medication commonly used to treat attention deficit hyperactivity disorder. The contract, awarded on August 12, 2025, represents a firm fixed price delivery order with an ultimate completion date of August 13, 2025. This award was competitively awarded with no set-aside designation and will be performed at the vendor's location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $2,143.13 to AmerisourceBergen Drug Corp for 100 capsules of Vyvanse 60 mg, a prescription stimulant medication commonly used to treat attention deficit hyperactivity disorder. The contract was awarded on August 12, 2025, with an ultimate completion date of August 13, 2025, under a firm fixed price arrangement with no set-aside designation. Performance will be executed at the contractor's facility in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order valued at $1,002.38 to AmerisourceBergen Drug Corp for 100 capsules of Vyvanse 40 mg, a prescription medication commonly used to treat attention deficit hyperactivity disorder. Issued on August 5, 2025, with an ultimate completion date of August 6, 2025, this firm fixed-price delivery order represents a single-transaction procurement under a competitive, non-set-aside arrangement. The product will be delivered to AmerisourceBergen's corporate...
- SPE2DB22D2005Indefinite Delivery Contract
- SPE2DB22D2005-SPE2DB25FJRL2Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,896.20 to AmerisourceBergen Drug Corp for 100 capsules of Vyvanse 30 mg, a prescription stimulant medication commonly used to treat attention deficit hyperactivity disorder and narcolepsy. The contract, executed on August 13, 2025, with an ultimate completion date of August 14, 2025, operates under a firm fixed price structure with no set-aside designation, indicating competitive award to this qualified pharmaceutical distributor. AmerisourceBergen Drug Corp performed the work at its corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen Drug Corp's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. This prime IDC serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply a wide range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. The DLA's Pharmaceutical Prime Vendor Global Program Generation V initiative is structured to make multiple awards across separate regions with multiple contractors, positioning AmerisourceBergen to serve the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.9k | 8/13/25 |